Icatibant is a bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE). Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin.
- Mechanism
- Curator reviewed · 1 reference
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding to the B2 receptor, thereby treating the clinical symptoms of an acute, episodic attack of HAE.
- Primary indication
- Icatibant is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.Curator reviewed · 2 structured indications
- Formula / weight
- C59H89N19O13S · 1304.54 Da
- First approval
- Canada, 2020 · United States, 2011 · European Union, 2020
- Code names
- HOE-140 · Hoechst 140 · JE 049
- Brand names
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Icatibant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account